PMID: 8472630Feb 1, 1993

Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results

Diabetes Research and Clinical Practice
M T YilmazF Sipahioğlu

Abstract

This prospective pilot study was undertaken to test the efficacy of oral methyl-prednisolone (MP) therapy at spontaneous remission phase of type 1 diabetes in intervening the course of the disease. Twenty-five type 1 diabetic patients who were classified as having a spontaneous remission (honeymoon) were divided into treatment and non-treatment groups on voluntary basis. Fifteen patients thus making up the treatment group (13 males and 2 females, mean age 23.8 +/- 6.2 years) received 0.7-1.0 mg/kg/day of MP p.o. for 2 weeks. The dose of the drug was then gradually diminished every week until 5 mg/day (approx. 0.1 mg/kg/day) and discontinued at 10 +/- 2 weeks. In case of hyperglycemia occurring in 12 of 15 patients due to the administration of steroid, insulin was used to normalize blood glucose levels (average 0.47 +/- 0.21 IU/kg/day). The non-treatment group (8 males and 2 females, mean age 21.8 +/- 8.9) did not receive any special medication or placebo except for insulin whenever necessary to regulate glycemia. Upon completion of protocol, all patients in treatment group displayed clinical remission with 10 still in non-insulin requiring remission for follow-up periods ranging between 16 and 91 months. The remaining 5 patient...Continue Reading

References

Nov 26, 2002·Journal of Hepatology·Jean François DufourJürg Reichen
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Sep 13, 2012·The Annals of Pharmacotherapy·Jessica W SkelleyJeffrey A Kyle
Nov 27, 2009·The New England Journal of Medicine·Mark D PescovitzType 1 Diabetes TrialNet Anti-CD20 Study Group

Citations

Mar 1, 1976·The American Journal of the Medical Sciences·J M Olefsky, G Kimmerling
Jan 1, 1978·Annual Review of Biochemistry·B SamuelssonC Malmsten
Jun 14, 1990·The New England Journal of Medicine·A M McGregor
Jan 1, 1986·Diabetes/metabolism Reviews·G C WeirS Bonner-Weir
Mar 2, 1989·The New England Journal of Medicine·S C ShahN E Simpson
Oct 1, 1989·Immunology Today·P Pozzilli, H Kolb
Jul 1, 1989·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·J R AlgerK A Hossmann
Sep 8, 1988·The New England Journal of Medicine·J SilversteinS Johnson
Jun 1, 1988·Immunology Today·G KroemerG Wick
Jan 1, 1987·Journal of Steroid Biochemistry·M M ComptonJ A Cidlowski
Feb 1, 1985·The Journal of Clinical Investigation·T R CuppsA S Fauci
Nov 30, 1968·Lancet·R Illig, A Prader
Nov 1, 1982·Acta paediatrica Scandinavica·M KnipH K Akerblom
Mar 1, 1980·The Journal of Pediatrics·M MenchiniG Chiumello
Jun 18, 1960·British Medical Journal·K W TAYLOR

Related Concepts

Autoantibodies
Acute-Phase Reaction
T-Lymphocyte
Remission, Spontaneous
C-Peptide
Pilot Projects
Islet cell surface antibodies
HLA-DR Antigens
Immune-Associated Antigens
Diabetes, Autoimmune

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.